Media

AAHI pioneers immune-enhancing platforms to provide potent, durable, broadly effective, and efficient vaccines and immunotherapies that are accessible to those who most need them.

NEWS & EVENTS

FILTER BY YEAR

The Challenges of Vaccine Transport and Storage

December 19, 2022

Technology Networks

Experimental COVID-19 Vaccine Offers Long-Term Protection Against Severe Disease

December 1, 2022

EurekaAlert!

Successful Lyophilization of a Thermostable Subunit Tuberculosis Vaccine Candidate Containing an Emulsion-Based Adjuvant

November 8, 2022

Lyophilization Technology

What Next-Gen Covid-19 Vaccines Might Look Like

November 3, 2022

Knowable Magazine

New Pan-Coronavirus Vaccine Passes Key Experiments, Demonstrates Protection

October 27, 2022

Duke Human Vaccine Institute

Page [tcb_pagination_current_page] of [tcb_pagination_total_pages]

First

Last

PRESS RELEASES

FILTER BY YEAR

The Access to Advanced Health Institute Announces $9.9M Award to Develop a Nasal Spray Influenza RNA Vaccine Through Phase 1 Clinical Trials

February 6, 2023

AAHI Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature

November 2, 2022

AAHI to Present Novel Applications of Its Unique Self-Amplifying RNA Vaccine Platform at the 10th International mRNA Health Conference

November 1, 2022

AAHI Contributes Its Unique Adjuvant Formulation Profiles to the National Institute of Health’s Vaccine Adjuvant Compendium

August 15, 2022

The Access to Advanced Health Institute Receives $26 Million Donation from the Chan Soon-Shiong Family Foundation to Further Develop Immune-Enhancing Platform Technology

April 11, 2022

Page [tcb_pagination_current_page] of [tcb_pagination_total_pages]

First

Last